NE3107
Phase 2Small molecule
NE3107 is one of 88 small molecule programs targeting Brain Injury. It is currently in Phase 2.
2
Indications
6
Total Trials
2
Active Trials
87
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
245 competitors in Brain Injury
#DrugCompanyPhaseTrials
1Epogen
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.Phase 3
Zyloprim
Alnylam PharmaceuticalsPhase 3
Brintellix
TakedaPhase 3
Epsom Salt
FFresenius Kabi Oncology Ltd.
Phase 3
Cyklokapron
AAmring
Phase 3
Nuvigil
NNuvo Research GmbH
Phase 3
Prometrium
FerringPhase 3
Seroquel
EEngelhard Arzneimittel GmbH & Co.KG
Phase 3
Rocephin
CConrado Roberto Hoffmann Filho
Phase 3
Botox
VVitae Pharmaceuticals Inc., an Allergan affiliate
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Dementia1 trial
Brain Injury1 trial
1 more indication
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for NE3107. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- BBioVie Inc.